Abstract
Objectives: To examine the cross-sectional association between functional performance and Alzheimer's disease (AD) neuroimaging biomarkers in individuals without dementia (cognitively unimpaired (CU), and those with mild cognitive impairment (MCI)). Design: Cross-sectional. Setting: Olmsted County, Minnesota. Participants: Population-based Mayo Clinic Study of Aging (MCSA) participants (aged ≥ 50, mean age 71.3 ± 10.2; 53.4% male; 28.3% apolipoprotein (APO)E ε4 allele carriers, 1,578 CU, 204 MCI) who underwent 11C-Pittsburgh compound B (11C-PiB) positron emission tomography (PET) (N=1,782). Measurements: We defined an abnormal (high) 11C-PiB-PET retention ratio as a standardized uptake value ratio greater than 1.42 (high amyloid; A+), abnormal (reduced) AD signature cortical thickness (neurodegeneration; N+) as less than 2.67 mm (MRI measurement), and biomarker groups according to the combination of abnormality (or not) for amyloid accumulation (A+/A–) and neurodegeneration (N+/N–). Functional performance was assessed using the Clinical Dementia Rating (CDR) Sum of Boxes (SOB) for functional domains and the Functional Activities Questionnaire (FAQ). Results: Participants with a CDR-SOB (functional) score greater than 0 were almost 4 times as likely to have N + (odds ratio (OR)=3.92, 95% confidence interval (CI)=1.77–8.67, adjusting for age, sex, education, global cognitive z-score, and APOE ε4 allele status; p<.001) and those with a FAQ score greater than 0 were 1.5 times as likely to have A + (OR=1.48, 95% CI=1.04–2.11, p=.03). Higher FAQ scores were associated with greater odds of A+N + and A–N + in CU participants. Conclusion: The findings of this cross-sectional study supplement limited available information that supports an association between functional performance and AD neuroimaging biomarkers very early in the dementia pathophysiology. The associations should be validated in longitudinal studies. J Am Geriatr Soc 66:2274–2281, 2018.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2274-2281 |
| Number of pages | 8 |
| Journal | Journal of the American Geriatrics Society |
| Volume | 66 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 1 2018 |
Fingerprint
Keywords
- amyloid
- CDR
- FAQ
- functional performance
- neurodegeneration
ASJC Scopus subject areas
- Geriatrics and Gerontology
Cite this
Association Between Functional Performance and Alzheimer's Disease Biomarkers in Individuals Without Dementia. / Vassilaki, Maria; Aakre, Jeremiah A.; Kremers, Walter K; Mielke, Michelle M; Geda, Yonas Endale; Machulda, Mary Margaret; Knopman, David S; Coloma, Preciosa M.; Schauble, Barbara; Vemuri, Prashanthi D; Lowe, Val; Jack, Clifford R Jr.; Petersen, Ronald Carl; Roberts, Rosebud O.
In: Journal of the American Geriatrics Society, Vol. 66, No. 12, 01.12.2018, p. 2274-2281.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Association Between Functional Performance and Alzheimer's Disease Biomarkers in Individuals Without Dementia
AU - Vassilaki, Maria
AU - Aakre, Jeremiah A.
AU - Kremers, Walter K
AU - Mielke, Michelle M
AU - Geda, Yonas Endale
AU - Machulda, Mary Margaret
AU - Knopman, David S
AU - Coloma, Preciosa M.
AU - Schauble, Barbara
AU - Vemuri, Prashanthi D
AU - Lowe, Val
AU - Jack, Clifford R Jr.
AU - Petersen, Ronald Carl
AU - Roberts, Rosebud O
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Objectives: To examine the cross-sectional association between functional performance and Alzheimer's disease (AD) neuroimaging biomarkers in individuals without dementia (cognitively unimpaired (CU), and those with mild cognitive impairment (MCI)). Design: Cross-sectional. Setting: Olmsted County, Minnesota. Participants: Population-based Mayo Clinic Study of Aging (MCSA) participants (aged ≥ 50, mean age 71.3 ± 10.2; 53.4% male; 28.3% apolipoprotein (APO)E ε4 allele carriers, 1,578 CU, 204 MCI) who underwent 11C-Pittsburgh compound B (11C-PiB) positron emission tomography (PET) (N=1,782). Measurements: We defined an abnormal (high) 11C-PiB-PET retention ratio as a standardized uptake value ratio greater than 1.42 (high amyloid; A+), abnormal (reduced) AD signature cortical thickness (neurodegeneration; N+) as less than 2.67 mm (MRI measurement), and biomarker groups according to the combination of abnormality (or not) for amyloid accumulation (A+/A–) and neurodegeneration (N+/N–). Functional performance was assessed using the Clinical Dementia Rating (CDR) Sum of Boxes (SOB) for functional domains and the Functional Activities Questionnaire (FAQ). Results: Participants with a CDR-SOB (functional) score greater than 0 were almost 4 times as likely to have N + (odds ratio (OR)=3.92, 95% confidence interval (CI)=1.77–8.67, adjusting for age, sex, education, global cognitive z-score, and APOE ε4 allele status; p<.001) and those with a FAQ score greater than 0 were 1.5 times as likely to have A + (OR=1.48, 95% CI=1.04–2.11, p=.03). Higher FAQ scores were associated with greater odds of A+N + and A–N + in CU participants. Conclusion: The findings of this cross-sectional study supplement limited available information that supports an association between functional performance and AD neuroimaging biomarkers very early in the dementia pathophysiology. The associations should be validated in longitudinal studies. J Am Geriatr Soc 66:2274–2281, 2018.
AB - Objectives: To examine the cross-sectional association between functional performance and Alzheimer's disease (AD) neuroimaging biomarkers in individuals without dementia (cognitively unimpaired (CU), and those with mild cognitive impairment (MCI)). Design: Cross-sectional. Setting: Olmsted County, Minnesota. Participants: Population-based Mayo Clinic Study of Aging (MCSA) participants (aged ≥ 50, mean age 71.3 ± 10.2; 53.4% male; 28.3% apolipoprotein (APO)E ε4 allele carriers, 1,578 CU, 204 MCI) who underwent 11C-Pittsburgh compound B (11C-PiB) positron emission tomography (PET) (N=1,782). Measurements: We defined an abnormal (high) 11C-PiB-PET retention ratio as a standardized uptake value ratio greater than 1.42 (high amyloid; A+), abnormal (reduced) AD signature cortical thickness (neurodegeneration; N+) as less than 2.67 mm (MRI measurement), and biomarker groups according to the combination of abnormality (or not) for amyloid accumulation (A+/A–) and neurodegeneration (N+/N–). Functional performance was assessed using the Clinical Dementia Rating (CDR) Sum of Boxes (SOB) for functional domains and the Functional Activities Questionnaire (FAQ). Results: Participants with a CDR-SOB (functional) score greater than 0 were almost 4 times as likely to have N + (odds ratio (OR)=3.92, 95% confidence interval (CI)=1.77–8.67, adjusting for age, sex, education, global cognitive z-score, and APOE ε4 allele status; p<.001) and those with a FAQ score greater than 0 were 1.5 times as likely to have A + (OR=1.48, 95% CI=1.04–2.11, p=.03). Higher FAQ scores were associated with greater odds of A+N + and A–N + in CU participants. Conclusion: The findings of this cross-sectional study supplement limited available information that supports an association between functional performance and AD neuroimaging biomarkers very early in the dementia pathophysiology. The associations should be validated in longitudinal studies. J Am Geriatr Soc 66:2274–2281, 2018.
KW - amyloid
KW - CDR
KW - FAQ
KW - functional performance
KW - neurodegeneration
UR - http://www.scopus.com/inward/record.url?scp=85056840117&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056840117&partnerID=8YFLogxK
U2 - 10.1111/jgs.15577
DO - 10.1111/jgs.15577
M3 - Article
C2 - 30462843
AN - SCOPUS:85056840117
VL - 66
SP - 2274
EP - 2281
JO - Journal of the American Geriatrics Society
JF - Journal of the American Geriatrics Society
SN - 0002-8614
IS - 12
ER -